🇺🇸 Mycophenolate Mofetil (MMF) in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 9

Most-reported reactions

1. Pneumonia — 2 reports (22.22%)
2. Adenovirus Infection — 1 report (11.11%)
3. Drug Level Decreased — 1 report (11.11%)
4. Mycobacterial Infection — 1 report (11.11%)
5. Pancreas Transplant Rejection — 1 report (11.11%)
6. Pemphigoid — 1 report (11.11%)
7. Therapeutic Response Decreased — 1 report (11.11%)
8. Unmasking Of Previously Unidentified Disease — 1 report (11.11%)

Source database →

Frequently asked questions

Is Mycophenolate Mofetil (MMF) approved in United States?

Mycophenolate Mofetil (MMF) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Mycophenolate Mofetil (MMF) in United States?

ITB-Med LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.